Ryan Francis Maguire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ryan Francis Maguire has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Stephen Yates
Artelo Bioscience, Ltd., Alderly Edge, Cheshire SK10 4TG, UK
1 shared publication - Saoirse Elizabeth O'SUllivan
School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK
1 shared publication - Sophie Anne Millar
Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, United Kingdom
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 219
Towards Better Delivery of Cannabidiol (CBD)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.
- 28 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 219
Top Cited PapersOpen AccessTowards Better Delivery of Cannabidiol (CBD)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.